Clear Search

Showing 3 results for “real-world” published 2023.

January 2024

Burden of Systemic Lupus Erythematosus in Clinical Practice: Baseline Data from the SLE Prospective Observational Cohort Study (SPOCS) by Interferon Gene Signature

Lupus Sci Med. 2023; 10(2):e001032 DOI: 10.1136/lupus-2023-001032

This study from Arnaud et al described baseline characteristics of SLE patients grouped by disease activity and IFNGS category in the international SPOCS study. IFNGS-high patients were younger at SLE diagnosis, and a baseline SLEDAI-2K score ≥10 was associated with shorter disease duration, more frequent and more severe flares. IFNGS-low patients were more likely to exhibit musculoskeletal and CNS comorbidities than IFNGS-high patients. Continuation of the SPOCS study will allow investigation into how different baseline characteristics affect long-term outcomes in SLE patients.

more…

December 2023

Efficacy and Safety of Telitacicept in Patients with Systemic Lupus Erythematosus: A Multicentre, Retrospective, Real-World Study

Lupus Sci. Med. 2023;10(2):e001074 DOI 10.1136/lupus-2023-001074

In this study, telitacicept add-on therapy demonstrated desirable real-world safety and efficacy profiles for the management of SLE, LN, and patients with haematological abnormalities.

more…

August 2023

SGLT2 Inhibitors Alleviated Podocyte Damage in Lupus Nephritis by Decreasing Inflammation and Enhancing Autophagy

Ann Rheum Dis. 2023 DOI: 10.1136/ard-2023-224242

Data revealed a renoprotective effect of SGLT2 inhibitors by reducing proteinuria and preserving renal function in the murine MRL/lpr lupus model.

more…